SCHEMBL1963085

SCHEMBL1963085

CC(C)CC(O)c1cc2cc(F)cnc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.35
PTGDR Q13258 1/20 0.35
NOD1 Q9Y239 3/20 0.35
NOD2 Q9HC29 1/20 0.35
ALDH3A1 P30838 1/20 0.33
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
SRC P12931 1/20 0.32
PSEN1 P49768 2/20 0.32
PSEN2 P49810 2/20 0.32
APH1B Q8WW43 2/20 0.32
NCSTN Q92542 2/20 0.32
APH1A Q96BI3 2/20 0.32
PSENEN Q9NZ42 2/20 0.32
LARS1 Q9P2J5 2/20 0.32
ACLY P53396 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1960993 0.83 RECQL (0.48) RECQLPTGDR2ALDH1A1KMT2ALMNA
SCHEMBL1962040 0.83 NAMPT (0.37) RECQLPTGDR2ALDH1A1KMT2AGAA
SCHEMBL27889569 0.83 ALDH1A1 (0.36) RECQLPTGDR2NOD1NOD2ALDH1A1
SCHEMBL1963563 0.81 RECQL (0.36) RECQLALDH1A1HTR6
SCHEMBL1959066 0.80 ALDH1A1 (0.39) RECQLPTGDR2PTGDRNOD1NOD2
SCHEMBL2043071 0.79 PPARG (0.38) RECQLPTGDR2PTGDRNOD1ALDH3A1
SCHEMBL1958741 0.79 RECQL (0.35) RECQLLMNA
SCHEMBL1960448 0.77 RECQL (0.41) RECQLPTGDR2PTGDRALDH3A1ALDH1A1
SCHEMBL27873115 0.74 GCK (0.34) RECQLPTGDR2PTGDRALDH1A1GAA
SCHEMBL30270502 0.72 PTGDR2 (0.49) PTGDR2PTGDRNOD1NOD2ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 RECQL 3296/4885PTGDR2 1782/4885PTGDR 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.